Cargando…

Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter

SIMPLE SUMMARY: Hypoxia is a common feature of solid tumors and associated with poor outcome in most cancer types and treatment modalities, including radiotherapy, chemotherapy, surgery and, most likely, immunotherapy. Emerging strategies, such as proton therapy and combination therapies with radiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hompland, Tord, Fjeldbo, Christina Sæten, Lyng, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866096/
https://www.ncbi.nlm.nih.gov/pubmed/33525508
http://dx.doi.org/10.3390/cancers13030499
_version_ 1783648001365901312
author Hompland, Tord
Fjeldbo, Christina Sæten
Lyng, Heidi
author_facet Hompland, Tord
Fjeldbo, Christina Sæten
Lyng, Heidi
author_sort Hompland, Tord
collection PubMed
description SIMPLE SUMMARY: Hypoxia is a common feature of solid tumors and associated with poor outcome in most cancer types and treatment modalities, including radiotherapy, chemotherapy, surgery and, most likely, immunotherapy. Emerging strategies, such as proton therapy and combination therapies with radiation and hypoxia targeted drugs, provide new opportunities to overcome the hypoxia barrier and improve therapeutic outcome. Hypoxia is heterogeneously distributed both between and within tumors and shows large variations across patients not only in prevalence, but importantly, also in level. To best exploit the emerging strategies, a better understanding of how individual hypoxia levels from mild to severe affect tumor biology is vital. Here, we discuss our current knowledge on this topic and how we should proceed to gain more insight into the field. ABSTRACT: Hypoxia arises in tumor regions with insufficient oxygen supply and is a major barrier in cancer treatment. The distribution of hypoxia levels is highly heterogeneous, ranging from mild, almost non-hypoxic, to severe and anoxic levels. The individual hypoxia levels induce a variety of biological responses that impair the treatment effect. A stronger focus on hypoxia levels rather than the absence or presence of hypoxia in our investigations will help development of improved strategies to treat patients with hypoxic tumors. Current knowledge on how hypoxia levels are sensed by cancer cells and mediate cellular responses that promote treatment resistance is comprehensive. Recently, it has become evident that hypoxia also has an important, more unexplored role in the interaction between cancer cells, stroma and immune cells, influencing the composition and structure of the tumor microenvironment. Establishment of how such processes depend on the hypoxia level requires more advanced tumor models and methodology. In this review, we describe promising model systems and tools for investigations of hypoxia levels in tumors. We further present current knowledge and emerging research on cellular responses to individual levels, and discuss their impact in novel therapeutic approaches to overcome the hypoxia barrier.
format Online
Article
Text
id pubmed-7866096
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78660962021-02-07 Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter Hompland, Tord Fjeldbo, Christina Sæten Lyng, Heidi Cancers (Basel) Review SIMPLE SUMMARY: Hypoxia is a common feature of solid tumors and associated with poor outcome in most cancer types and treatment modalities, including radiotherapy, chemotherapy, surgery and, most likely, immunotherapy. Emerging strategies, such as proton therapy and combination therapies with radiation and hypoxia targeted drugs, provide new opportunities to overcome the hypoxia barrier and improve therapeutic outcome. Hypoxia is heterogeneously distributed both between and within tumors and shows large variations across patients not only in prevalence, but importantly, also in level. To best exploit the emerging strategies, a better understanding of how individual hypoxia levels from mild to severe affect tumor biology is vital. Here, we discuss our current knowledge on this topic and how we should proceed to gain more insight into the field. ABSTRACT: Hypoxia arises in tumor regions with insufficient oxygen supply and is a major barrier in cancer treatment. The distribution of hypoxia levels is highly heterogeneous, ranging from mild, almost non-hypoxic, to severe and anoxic levels. The individual hypoxia levels induce a variety of biological responses that impair the treatment effect. A stronger focus on hypoxia levels rather than the absence or presence of hypoxia in our investigations will help development of improved strategies to treat patients with hypoxic tumors. Current knowledge on how hypoxia levels are sensed by cancer cells and mediate cellular responses that promote treatment resistance is comprehensive. Recently, it has become evident that hypoxia also has an important, more unexplored role in the interaction between cancer cells, stroma and immune cells, influencing the composition and structure of the tumor microenvironment. Establishment of how such processes depend on the hypoxia level requires more advanced tumor models and methodology. In this review, we describe promising model systems and tools for investigations of hypoxia levels in tumors. We further present current knowledge and emerging research on cellular responses to individual levels, and discuss their impact in novel therapeutic approaches to overcome the hypoxia barrier. MDPI 2021-01-28 /pmc/articles/PMC7866096/ /pubmed/33525508 http://dx.doi.org/10.3390/cancers13030499 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hompland, Tord
Fjeldbo, Christina Sæten
Lyng, Heidi
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
title Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
title_full Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
title_fullStr Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
title_full_unstemmed Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
title_short Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
title_sort tumor hypoxia as a barrier in cancer therapy: why levels matter
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866096/
https://www.ncbi.nlm.nih.gov/pubmed/33525508
http://dx.doi.org/10.3390/cancers13030499
work_keys_str_mv AT homplandtord tumorhypoxiaasabarrierincancertherapywhylevelsmatter
AT fjeldbochristinasæten tumorhypoxiaasabarrierincancertherapywhylevelsmatter
AT lyngheidi tumorhypoxiaasabarrierincancertherapywhylevelsmatter